Tillotson S L, Fuggle P W, Smith I, Ades A E, Grant D B
MRC Register for Children with Congenital Hypothyrodism, Institute of Child Health, London.
BMJ. 1994 Aug 13;309(6952):440-5. doi: 10.1136/bmj.309.6952.440.
To assess whether early treatment of congenital hypothyroidism fully prevents intellectual impairment.
A national register of children with congenital hypothyroidism who were compared with unaffected children from the same school classes and matched for age, sex, social class, and first language.
First three years (1982-4) of a neonatal screening programme in England, Wales, and Northern Ireland.
361 children with congenital hypothyroidism given early treatment and 315 control children.
Intelligence quotient (IQ) measured at school entry at 5 years of age with the Wechsler preschool and primary scale of intelligence.
There was a discontinuous relation between IQ and plasma thyroxine concentration at diagnosis, with a threshold at 42.8 nmol/l (95% confidence interval 35.2 to 47.1 nmol/l). Hypothyroid children with thyroxine values below 42.8 nmol/l had a mean IQ 10.3 points (6.9 to 13.7 points) lower than those with higher values and than controls. None of the measures of quality of treatment (age at start of treatment (range 1-173 days), average thyroxine dose (12-76 micrograms in the first year), average thyroxine concentration during treatment (79-234 nmol/l in the first year), and thyroxine concentration less than 103 nmol/l at least once during the first year) influenced IQ at age 5.
Despite early treatment in congenital hypothyroidism the disease severity has a threshold effect on brain development, probably determined prenatally. The 55% of infants with more severe disease continue to show clinically significant intellectual impairment; infants with milder disease show no such impairment. The findings predict that 10% of early treated infants with severe hypothyroidism, compared with around 40% of those who presented with symptoms in the period before screening began, are likely to require special education.
评估先天性甲状腺功能减退症的早期治疗能否完全预防智力损害。
一项针对先天性甲状腺功能减退症患儿的全国性登记研究,将这些患儿与来自同班级、年龄、性别、社会阶层及第一语言相匹配的未患病儿童进行比较。
英格兰、威尔士和北爱尔兰新生儿筛查项目的头三年(1982 - 1984年)。
361名接受早期治疗的先天性甲状腺功能减退症患儿和315名对照儿童。
在5岁入学时使用韦氏学前及初小儿童智力量表测量智商(IQ)。
诊断时IQ与血浆甲状腺素浓度之间存在不连续关系,阈值为42.8 nmol/l(95%置信区间35.2至47.1 nmol/l)。甲状腺素值低于42.8 nmol/l的甲状腺功能减退患儿的平均IQ比甲状腺素值较高的患儿及对照儿童低10.3分(6.9至13.7分)。治疗质量的各项指标(开始治疗的年龄(范围1 - 173天)、第一年的平均甲状腺素剂量(12 - 76微克)、治疗期间的平均甲状腺素浓度(第一年79 - 234 nmol/l)以及第一年至少有一次甲状腺素浓度低于103 nmol/l)均未影响5岁时的IQ。
尽管先天性甲状腺功能减退症进行了早期治疗,但疾病严重程度对大脑发育有阈值效应,可能由产前因素决定。55%病情较重的婴儿继续表现出具有临床意义的智力损害;病情较轻的婴儿则未出现此类损害。研究结果预测,与筛查开始前出现症状的婴儿中约40%相比,10%早期接受治疗的重度甲状腺功能减退症婴儿可能需要特殊教育。